AL patients don't dare go without dara

Research output: Contribution to journalReview articlepeer-review

Abstract

In this issue of Blood, 3 papers by the teams of Roussel et al, Sanchorawala et al, and Kimmich et al demonstrate high rates of efficacy and low rates of toxicity of single-agent daratumumab (dara) in patients with previously treated immunoglobulin light-chain (AL) amyloidosis.1-3 These 3 reports include 2 small phase 2 prospective trials employing single-agent dara1,2 and a compilation of 168 consecutive patients treated with either daratumumab and dexamethasone (DD) or bortezomib and DD (DVD).3 Among previously treated AL patients, dara with low-intensity corticosteroid yielded partial hematologic response (PR) or better and very good partial response (VGPR) or better in 64% to 90% and in 56% to 86% of patients, respectively.1-3 Progression-free survival (PFS) ranged from 12 to 28 months. Renal and cardiac responses were observed in 24% to 67% and 22% to 50% of patients, respectively. The vast majority of hematologic responses occurred after the first 4 doses of dara.

Original languageEnglish (US)
Pages (from-to)1509-1510
Number of pages2
JournalBlood
Volume135
Issue number18
DOIs
StatePublished - Apr 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'AL patients don't dare go without dara'. Together they form a unique fingerprint.

Cite this